Insmed to Present at Three November Conferences

BRIDGEWATER, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following investor conferences:

• The Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:20 a.m. MST.
• The Stifel 2018 Healthcare Conference in New York, NY on Wednesday, November 14, 2018 at 12:30 p.m. ET.
• The Evercore ISI HealthconX Conference in Boston, MA on Wednesday, November 28, 2018 at 11:20 a.m. ET.

These presentations will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcasts will be archived for a period of 90 days following the conclusion of each live event.

About InsmedInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

Contact:Blaine Davis Insmed Incorporated (908) 947-2841 [email protected]

You May Also Be Interested In

• Cantor Fitzgerald Reiterates Overweight Rating on Insmed (INSM) Ahead of Q2 Results
• Cohen & Company Sets Release Date for Second Quarter 2026 Financial Results
• Peak Discovery Extends Non-Binding Letter of Intent and Provides Update on Private Placement